intralesional rituximab in pemphigus vulgaris

comparison between the efficacy of intralesional rituximab and intralesional triamcinolone in the treatment of patients with refractory pemphigus vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181224042105N1

Enrollment

Registered

2019-01-01

Start date

2017-11-22

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pemphigus vulgaris. Pemphigus vulgaris

Interventions

Intervention 1: Intervention group 1: 1cc intralesional ritumab10 mg/ml will be injected in 21 lesions and after one month will be repeated. Intervention 2: Intervention group 1: 1cc intralesional t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory lesions of pemphigus vulgaris in the scalp and oral cavity after 4 mounths of systemic therapy No contraindication for rituximab

Exclusion criteria

Exclusion criteria: Any contraindication for rituximab

Design outcomes

Primary

Measure	Time frame
Percentage of size variation in pemphigus lesions. Timepoint: Measurement of size of the lesions on day 1 and 30 and then mounth6. Method of measurement: Ruler and medical thermometer.	—

Secondary

Measure	Time frame
Visual Analogue Scale. Timepoint: day 0 and 30 and then mounth6. Method of measurement: Asking from patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Danesh

Esfahan University of Medical Sciences

fdanesh2005@gmail.com+98 31 3264 3327

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026